Association of the cardiometabolic index with sarcopenia among U.S. adults: NHANES 2011–2018 findings
PLOS One · 2025
DOI: 10.1371/journal.pone.0323905 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Qing Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Sarcopenia, Cardiovascular Diseases, Metabolic Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University, 2023 Undergraduate Education and Teaching Reform Research Project of the School of Medicine and Integrative Medicine, Nanjing University of Chinese Medicine.
Abstract (Originalsprache)
Background
The cardiometabolic index (CMI), initially devised as a diagnostic tool for diabetes mellitus, has evolved into a composite biomarker for evaluating metabolic syndrome and cardiovascular disease risk. In order to shed light on any possible interactions between sarcopenia and CMI, this study will look at the relationship between the two. Methods and results Data from the 2011–2018 National Health and Nutrition Examination Survey (NHANES) were analyzed to investigate the possible link between sarcopenia and CMI. Among 3,185 eligible participants, the weighted prevalence of sarcopenia was 7.84%. A significant positive association emerged between CMI and sarcopenia risk, with each unit increase in CMI was linked with a 12% greater risk of sarcopenia in the fully adjusted model (OR: 1.12; 95% CI: 1.01–1.26). Moreover, dose-response relationships were evident across CMI tertiles ( P for trend < 0.05). Subgroup analyses and interaction tests indicated that the positive correlation between CMI and the risk of sarcopenia differs significantly across subgroups defined by education level, sedentary time and CVD status (all P for interaction < 0.05).
Conclusions
Our findings demonstrate a robust association between elevated CMI levels and increased sarcopenia risk, suggesting CMI’s potential utility as a clinical biomarker for sarcopenia risk surveillance. To confirm these results and demonstrate causality, more research is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Nutrition, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
ORCID-Profile: Qing Zhao
Förderung
- Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
- 2023 Undergraduate Education and Teaching Reform Research Project of the School of Medicine and Integrative Medicine, Nanjing University of Chinese Medicine
Zitieren
APA
Zhao, Q., Xu, Y., & Chen, X. (2025). Association of the cardiometabolic index with sarcopenia among U.S. adults: NHANES 2011–2018 findings. PLOS One. https://doi.org/10.1371/journal.pone.0323905
Vancouver
Zhao Q, Xu Y, Chen X. Association of the cardiometabolic index with sarcopenia among U.S. adults: NHANES 2011–2018 findings. PLOS One. 2025. doi:10.1371/journal.pone.0323905
BibTeX
@article{Zhao2025,
author = {Zhao, Qing and Xu, Yue and Chen, Xiaotian},
title = {Association of the cardiometabolic index with sarcopenia among U.S. adults: NHANES 2011–2018 findings},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323905}
}
EUVIMED